Introduction

After more than three years of litigation in the Delaware District Court, C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. v. AngioDynamics, Inc. (Case No. 1:21-cv-00349) concluded through a confidential settlement and stipulated dismissal with prejudice in April 2024. Filed in March 2021, this venous access port patent infringement dispute centered on three issued U.S. patents and a range of commercially significant implantable port products—placing hundreds of millions of dollars in medical device market share squarely in the crosshairs of litigation.

The case carries meaningful implications for medical device patent litigation strategy, particularly in the competitive vascular access market where product differentiation, FDA clearance pathways, and IP portfolio management intersect. For patent attorneys, in-house counsel, and R&D teams operating in this space, the trajectory of this case—from aggressive multi-patent assertion to private settlement—reflects broader trends in how high-stakes medical device IP disputes are resolved in Delaware federal courts.

Case Overview

The Parties

The Patents at Issue

This case involved three U.S. patents relating to implantable venous access port technology—devices surgically placed beneath the skin to provide repeated vascular access for chemotherapy, IV medications, and blood draws. The asserted claims likely cover structural and functional innovations in port design, power-injectable functionality, and infusion set configurations.

• • U.S. Patent No. 9,603,993 B2 (App. No. 13/853,961) — Related to structural and functional innovations in port design.
• • U.S. Patent No. 9,603,992 B2 (App. No. 13/853,956) — Related to power-injectable functionality.
• • U.S. Patent No. 8,025,639 B2 (App. No. 12/419,957) — Covering infusion set configurations and overall port architecture.

The Accused Products

AngioDynamics’ accused product line was substantial and commercially significant, including Smart Port® CT Mini power-injectable port, Smart Port® CT low-profile power injectable port, Smart Port® CT power-injectable port, BioFlo Ports with Endexo technology, Xcela Plus ports, LifePort® infusion sets, and LifeGuard™ safety infusion set. The breadth of accused products signals that Bard’s infringement theory targeted AngioDynamics’ core vascular access portfolio.

Legal Representation

Plaintiff was represented by Morris, Nichols, Arsht & Tunnell LLP, with lead attorney Jack B. Blumenfeld—one of Delaware’s most prominent patent litigators. Defendant retained a three-firm defense coalition: DLA Piper LLP (US), Duane Morris LLP, and Potter, Anderson & Corroon LLP, deploying a large team of seventeen attorneys including Andrew J. Harris, David Ellis Moore, and Bindu Ann George Palapura, among others. The size of AngioDynamics’ legal team underscores the commercial stakes involved.

Litigation Timeline & Procedural History

Bard filed its complaint on March 8, 2021, in the United States District Court for the District of Delaware—a predictable but strategically deliberate venue choice. The case formally closed on April 8, 2024, approximately 37 months after filing. This duration is consistent with standard Delaware patent litigation timelines, suggesting neither accelerated nor abnormally protracted proceedings. The absence of a trial date in the outcome record indicates the parties resolved their dispute before reaching the courtroom.

The Verdict & Legal Analysis

Outcome

The case terminated through a stipulated dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41, filed jointly by both parties and entered by the court on April 8, 2024. The dismissal was grounded in a confidential Settlement Agreement—the specific financial terms of which were not disclosed in public filings.

Critically, the stipulation includes a mutual waiver of rights under 35 U.S.C. § 285, the fee-shifting statute that permits courts to award attorney’s fees in “exceptional” patent cases. Each party agreed to bear its own costs, fees, and expenses. All pending motions were rendered moot upon entry of the dismissal order. The court retained jurisdiction to enforce the settlement.

Legal Significance

While no published opinions or precedential claim construction rulings emerged from this case, several legally significant observations apply:

• Multi-patent assertion strategy: Bard’s use of three patents across overlapping technology areas reflects a portfolio bundling approach designed to increase litigation cost and settlement pressure on the defendant.
• Delaware venue dynamics: The filing confirms Delaware’s continued dominance as plaintiff-preferred patent litigation forum for medical device IP disputes.
• § 285 waiver as settlement tool: The explicit statutory waiver signals a clean-break resolution, reducing post-settlement litigation risk for both parties.

Industry & Competitive Implications

The vascular access port market is a multi-billion-dollar segment of the broader oncology and interventional radiology device industry. Bard/BD and AngioDynamics are two of a small number of established competitors, meaning IP disputes between them carry outsized market significance.

The settlement preserves competitive status quo in the short term—AngioDynamics’ Smart Port® and BioFlo product lines remain on the market. However, confidential settlement terms may include licensing royalties, design modifications, or market access restrictions that are not visible in public filings. Industry observers should monitor AngioDynamics’ product roadmap and any design updates to its port product lines as potential indicators of settlement obligations.

This case also reflects a broader trend in medical device patent litigation: sophisticated plaintiffs using continuation patent portfolios to reassert protection over mature technology areas as original patents near expiration. Companies relying on second-generation or “biologically enhanced” port designs (such as AngioDynamics’ Endexo technology) should proactively assess whether such innovations provide sufficient design differentiation to avoid future infringement exposure.